ClinicalTrials.gg
Not yet recruitingNCT06073808AmnioFixUpdated Nov 20, 2026

The Role of Amnion Membrane Allografts in Nipple Preservation

An interventional study of AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft and Control Device in Mastectomy, Gender Affirmation Surgery and Nipple Sparing Mastectomy, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 15 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
15 Years to 75 Years
Sex
All
01

Study summary

The overall objective of this proposal is to conduct a randomized-controlled study to determine whether treatment with dehydrated human amnion/chorion membrane (dHACMs) allografts can improve NAC viability in patients undergoing nipple sparing mastectomy (NSM). dHACM allografts are commercially available tissue membranes with biocompatible extracellular matrix and growth factors that have been shown to improve wound healing in patients with chronic and lower extremity wounds. To date, no study has evaluated the impact of dHACMs on NAC preservation following NSM. Investigators hypothesize that subareolar surgical implantation of dHACM allografts at time of NSM will reduce NAC necrosis and improve viability.

Read the detailed description

This proposal will be the first clinical trial to evaluate the clinical efficacy of dHACM allografts in NSM. The topic of study not only addresses a critically unmet need in the field of plastic surgery, but also maintains exceptional scientific and clinical merit. This study would be the first to establish dHACM allografts as a novel, innovative, and biologically-based adjunctive mechanism to improve vascularity and wound healing following NSM. Such findings would not only provide the evidence-base for widespread implementation of dHACM allografts in the surgical management of breast patients, but also serve as a catalyst to study the clinical efficacy of these allografts in other plastic surgical patient cohorts. Overall, this proposal aims to serve as a successful translational model incorporating scalable, biologically-based regenerative therapies in a surgical population.

Nipple necrosis is a major complication after nipple sparing mastectomy, a procedure that is commonly performed in the human population for gender reassignment surgery and for breast cancer prevention. This study will assess the efficacy of dHACMs can improve nipple viability after NSM.

02

Conditions studied

  • Mastectomy
  • Gender Affirmation Surgery
  • Nipple Sparing Mastectomy
  • Prophylactic Mastectomy
  • Benign Breast Condition

Keywords

  • nipple sparing mastectomy
  • gender affirming surgery
03

In context

Lead sponsor

Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biologically female with documented diagnosis of gender dysphoria, desire to undergo gender affirming surgery (female-to-male) NSM, and age 15 years of age or older.
  • Biological female, age 18 to 75 years old, who desire to undergo bilateral prophylactic NSM for nonmalignant breast conditions or to reduce the risk of breast cancer.

Exclusion criteria

Exclusion Criteria:

  • Current use
  • Known connective tissue disorder
  • Known neuropathy
  • Known history of breast cancer
  • History of breast radiotherapy
  • Pregnant or nursing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Assess dHACM viability

    Implantation of dHACM in patients during Nipple Sparing Mastectomy; test arm. The device will be implanted in one breast per patient during bilateral nipple sparing mastectomy.

    Device: AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft

  • Active comparator
    Assess dHACM effectiveness against control device

    Implantation of control device in patients during Nipple Sparing Mastectomy; control arm. The device will be implanted in one breast per patient during bilateral nipple sparing mastectomy.

    Device: Control Device

Interventions

  • DeviceAmnioFix dehydrated Human Amnion/Chorion Membrane Allograft

    Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.

    Also known as: AmnioFix

  • DeviceControl Device

    Control device will be applied to non-experimental breast. Each patient will serve as their own control.

06

What researchers measure

Primary outcomes

  1. Rate of Nipple Necrosis in patients who receive dHACM during nipple sparing mastectomy (NSM)

    The primary endpoint of this study is number of nipples with necrosis as defined by dark blue or black nipple discoloration, ultimately resulting in scabs or open wounds up to 3 months post-operatively.

    Time frame: through study completion, an average of 3 months post op

Secondary outcomes

  1. Rate of Nipple Healing

    Number of nipples that have healed per clinician assessment.

    Time frame: through study completion, an average of 3 months post op

  2. Degree of nipple loss

    Number of nipples partially or wholly lost to necrosis.

    Time frame: through study completion, an average of 3 months post op

  3. Nipple perfusion

    Perfusion of blood in the nipple assessed via indocyanine green (ICG)-SPY technology.

    Time frame: through study completion, an average of 3 months post op

  4. Aesthetic satisfaction scale score; scale used is a likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied

    Participant-rated satisfaction.

    Time frame: through study completion, an average of 3 months post op

  5. Number of Participants with Nipple Sensation

    Participants indicated whether they have nipple sensation (innervation) (Y/N).

    Time frame: through study completion, an average of 3 months post op

07

Study locations

1 site
  • Division of Plastic & Reconstructive Surgery
    Palo Alto, California 94304, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Jun 2026 → Jan 2027, primary completion Sep 2026 → Jan 2028 and completion Sep 2026 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2023
First posted
Oct 10, 2023
StartEst.
Jan 1, 2027was Jun 2026
Primary completionEst.
Jan 2028was Sep 2026
CompletionEst.
Jul 2028was Sep 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Jan 1, 2027
Nov 20, 2026
Primary completion
Sep 2026→Jan 2028
Nov 20, 2026
Study completion
Sep 2026→Jul 2028
Nov 20, 2026
Contact
Study contact changed: k•••@stanford.edu · •••6004→e•••@stanford.edu · •••6004. See the current contact
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Jun 1, 2026→Jan 1, 2027
    Primary completion Sep 2026→Jan 2028
    Study completion Sep 2026→Jul 2028
    Contact Study contact changed: k•••@stanford.edu · •••6004→e•••@stanford.edu · •••6004. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06073808
Responsible party
Dung Nguyen (Clinical Professor, Director of Breast Reconstruction, Director of Adult Plastics and Reconstructive Clinic, Associate Director of Microsurgery, Stanford University) — Principal investigator
First posted
Oct 10, 2023
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Elizabeth Tadevosyan
Contact
etadyan@stanford.edu
650-498-6004
Dung Nguyen, MD, PharmD
Contact
nguyendh@stanford.edu
Dung Nguyen, MD, PharmD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion